Progress of diffuse large B-cell lymphoma
10.3760/cma.j.issn.1009-9921.2018.01.003
- VernacularTitle:弥漫大B细胞淋巴瘤研究最新进展
- Author:
Yajun LI
1
;
Xi ZHU
;
Hui ZHOU
Author Information
1. 湖南省肿瘤医院 中南大学湘雅医学院附属肿瘤医院淋巴瘤血液内科
- Keywords:
Lymphoma;
large B-cell;
diffuse;
Therapeutic advance
- From:
Journal of Leukemia & Lymphoma
2018;27(1):8-11
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoma in adults, which is a highly heterogeneous of lymphoma with different biological characteristics, clinical manifestations, response to treatment and different prognosis for different patients. Although the curative rate of DLBCL patients has been improved because of the immunotherapy based on the R-CHOP treatment, 40％of patients will be resistant to the treatment or relapse after the remission at the early stage with poor prognosis. This article summarizes the recent progress of DLBCL including new molecular typing, new target drug development and treatment of relapsed /refractory patients according to the 59th American Society of Hematology Annual Meeting.
